Sysmex Corporation ADR (OTCMKTS:SSMXY) Sees Significant Growth in Short Interest

Sysmex Corporation ADR (OTCMKTS:SSMXY - Get Free Report) saw a large growth in short interest in the month of December. As of December 15th, there was short interest totaling 39,629 shares, a growth of 132.5% from the November 30th total of 17,047 shares. Currently, 0.0% of the company's shares are sold short. Based on an average daily trading volume, of 919,063 shares, the days-to-cover ratio is currently 0.0 days. Based on an average daily trading volume, of 919,063 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.0% of the company's shares are sold short.Sysmex Price PerformanceSysmex stock opened at $9.83 on Friday. The firm has a fifty day moving average of $10.23 and a 200-day moving average of $13.08. Sysmex has a 52-week low of $9.00 and a 52-week high of $20.31. The company has a quick ratio of 2.49, a current ratio of 3.34 and a debt-to-equity ratio of 0.11. The firm has a market capitalization of $6.19 billion, a P/E ratio of 19.66 and a beta of 1.17. Sysmex (OTCMKTS:SSMXY - Get Free Report) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $0.16 earnings per share for the quarter, hitting analysts' consensus estimates of $0.16. Sysmex had a net margin of 9.32% and a return on equity of 9.86%. The firm had revenue of $826.60 million during the quarter, compared to analysts' expectations of $880.80 million. As a group, analysts predict that Sysmex will post 0.57 EPS for the current year. Analyst Ratings ChangesSeparately, The Goldman Sachs Group raised shares of Sysmex from a "hold" rating to a "buy" rating in a research report on Thursday, October 9th. One investment analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy".View Our Latest Analysis on SSMXYAbout Sysmex (Get Free Report)Sysmex Corporation OTCMKTS: SSMXY is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex's product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics. The company's core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.Recommended StoriesFive stocks we like better than SysmexDo not delete, read immediatelyINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffCan Any Expenses Be Deducted From Capital Gains Tax?Do you know what Amazon is planning for January 1?Buffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Sysmex Right Now?Before you consider Sysmex, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sysmex wasn't on the list.While Sysmex currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here